BioLife Solutions, Inc. Stock

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
17.19 USD +1.00% Intraday chart for BioLife Solutions, Inc. +13.54% +5.78%
Sales 2024 * 111M Sales 2025 * 134M Capitalization 779M
Net income 2024 * -46M Net income 2025 * -23M EV / Sales 2024 * 6.99 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.81 x
P/E ratio 2024 *
-16.8 x
P/E ratio 2025 *
-33.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.00%
1 week+13.54%
Current month-7.33%
1 month-7.68%
3 months-1.32%
6 months+74.34%
Current year+5.78%
More quotes
1 week
15.42
Extreme 15.421
18.02
1 month
14.84
Extreme 14.84
19.18
Current year
14.50
Extreme 14.5
19.18
1 year
8.92
Extreme 8.9201
24.50
3 years
8.92
Extreme 8.9201
60.67
5 years
7.37
Extreme 7.37
60.67
10 years
1.43
Extreme 1.4328
60.67
More quotes
Managers TitleAgeSince
Founder 52 97-12-31
Chief Executive Officer 63 16-03-03
Director of Finance/CFO 39 14-12-31
Members of the board TitleAgeSince
Chief Executive Officer 63 16-03-03
Director/Board Member 62 13-11-17
Director/Board Member 62 22-08-31
More insiders
Date Price Change Volume
24-04-24 17.19 +1.00% 522,805
24-04-23 17.02 +1.31% 527,610
24-04-22 16.8 +5.93% 560,006
24-04-19 15.86 0.00% 475,138
24-04-18 15.86 +4.76% 601,209

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
17.19 USD
Average target price
23.12 USD
Spread / Average Target
+34.53%
Consensus